[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341817-105":59,"doc-detail-341817-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","il-22-a-key-inflammatory-mediator-as-a-biomarker-and-potential-therapeutic-target-for-lung-cancer","IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer","","Lung cancer causes extensive cancer-related mortality worldwide, and effective biomarkers are still lacking for accurate diagnosis and treatment. This review analyzes interleukin-22 (IL-22), an IL-10 family cytokine, focusing on how IL-22 signals through IL-22R1/IL-10R2 to regulate proliferation, anti-apoptotic pathways, tissue regeneration, and immune defense. Evidence links IL-22 dysregulation to cancer development across multiple organs. The review summarizes IL-22 expression, regulatory roles, and potential clinical value in lung cancer and highlights future research directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/il-22-a-key-inflammatory-mediator-as-a-biomarker-and-potential-therapeutic-target-for-lung-cancer/341817/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/il-22-a-key-inflammatory-mediator-as-a-biomarker-and-potential-therapeutic-target-for-lung-cancer/341817.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are biomarkers important in lung cancer management?","Question",{"text":112,"@type":113},"Lung cancer has no sufficient effective and accurate biomarkers for diagnosing and treating the disease. This gap motivates research into new molecular indicators.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does IL-22 exert its biological functions?",{"text":117,"@type":113},"IL-22 binds to heterodimeric receptors containing IL-22R1 and IL-10R2. This activates downstream pathways, including JAK/STAT, p38 MAPK, and PI3K/AKT, leading to effects such as survival signaling, migration, and tissue regeneration.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship does IL-22 have with lung cancer?",{"text":121,"@type":113},"Studies show IL-22 is upregulated in patients with non-small cell lung cancer, including in serum, malignant pleural effusion, and tumor tissues. IL-22Rα1 levels in tumor cells and tissues are also increased, suggesting clinical relevance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341817,1790766210,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Heliyon 10 (2024) e35901  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \n| Review article\u003Cbr>IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer\u003Cbr>Ling Xu a, 1 , Peng Cao a, 1 , Jianpeng Wang b, 1 , Peng Zhang a , Shuhui Hua , Chao Chenga , Hua Wang c, *\u003Cbr>a Department of Interventional Pulmonary Diseases, The Anhui Chest Hospital, Hefei, China b First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China\u003Cbr>c Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: IL-22 Lung cancer Biomarker\u003Cbr>Inflammation immunology |  | Lung cancer, one of the most prevalent cancers worldwide, stands as the primary cause of cancerrelated deaths. As is well-known, the utmost crucial risk factor contributing to lung cancer is smoking. In recent years, remarkable progress has been made in treating lung cancer, particularly non-small cell lung cancer (NSCLC). Nevertheless, the absence of effective and accurate biomarkers for diagnosing and treating lung cancer remains a pressing issue. Interleukin 22 (IL-22) is a member of the IL-10 cytokine family. It exerts biological functions (including induction of proliferation and anti-apoptotic signaling pathways, enhancement of tissue regeneration and immunity defense) by binding to heterodimeric receptors containing type 1 receptor chain (R1) and type 2 receptor chain (R2). IL-22 has been identified as a pro-cancer factor since dysregulation of the IL-22-IL-22R system has been implicated in the development of different cancers, including lung, breast, gastric, pancreatic, and colon cancers. In this review, we discuss the differential expression, regulatory role, and potential clinical significance of IL-22 in lung cancer, while shedding light on innovative approaches for the future. |\n\n1. Introduction  \nLung cancer is a heterogeneous disease in which cells in the lung grow aberrantly culminating in the formation of tumors. Typically, these tumors present as nodules or masses discernible through pulmonary imaging techniques [1]. In the year 2020, the global incidence of lung cancer surpassed a staggering 2.2 million cases, leading to approximately 1.8 million tragic fatalities. When considering age-standardized rates, the morbidity and mortality figures stand at 22.4 and 18.0 per 100,000 individuals respectively [2]. Generally, lung cancer is considered to be intricately linked to a multitude offactors including but not limited to smoking, genetic predisposition, occupational exposures, as well as the deleterious effects of air and environmental pollution [3,4]. Among the risk factors for lung cancer, smoking dominates overwhelmingly, with about two-thirds of lung cancer deaths globally caused by it [5]. In recent years, the drug resistance phenomenon of lung cancer to chemotherapy and targeted therapy has become more and more prominent [6–8]. Therefore, it is of heightened importance to find new therapeutic targets.  \n* Corresponding author. Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, China. [E-mail address:](E-mail address: wanghua@ahmu.edu.cn)[ wanghua@ahmu.edu.cn](E-mail address: wanghua@ahmu.edu.cn) (H. Wang).  \n1 These authors have contributed equally to this work and share first authorship.  \n[https://doi.org/10.1016/j.heliyon.2024.e35901](https://doi.org/10.1016/j.heliyon.2024.e35901)  \nReceived 13 August 2023; Received in revised form 5 August 2024; Accepted 6 August 2024 Available online 10 August 2024  \n2405-8440/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license ([http://c","cbCaiiBXT1OMJstx","https://ap.wps.com/l/cbCaiiBXT1OMJstx","pdf",3342958,14,"English","# Introduction\n## IL-22 biology and signaling\n## IL-22 dysregulation in cancer\n## IL-22 and lung cancer research background","[{\"question\":\"Why are biomarkers important in lung cancer management?\",\"answer\":\"Lung cancer has no sufficient effective and accurate biomarkers for diagnosing and treating the disease. This gap motivates research into new molecular indicators.\"},{\"question\":\"How does IL-22 exert its biological functions?\",\"answer\":\"IL-22 binds to heterodimeric receptors containing IL-22R1 and IL-10R2. This activates downstream pathways, including JAK/STAT, p38 MAPK, and PI3K/AKT, leading to effects such as survival signaling, migration, and tissue regeneration.\"},{\"question\":\"What relationship does IL-22 have with lung cancer?\",\"answer\":\"Studies show IL-22 is upregulated in patients with non-small cell lung cancer, including in serum, malignant pleural effusion, and tumor tissues. IL-22Rα1 levels in tumor cells and tissues are also increased, suggesting clinical relevance.\"}]","IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer | PDF",1790043970,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edea8686e2ca87e668ea87ade58ef542.webp",983,1341,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/038e5e01252008cd8bb2ee6895a85f85.webp",982,1340,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/632bf68d0e0ae920c387ba6238c40ec6.webp",981,1338,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd2ab1239bc2ca3c1a240092f2a44180.webp",980,1337]